CRTX News and Press, Cortexyme Inc. From 06/15/20

Welcome to the ten-year anniversary edition of Insider Weekends. Little did we know that we would end up publishing this series of articles continuously for 10 years when we introduced Insider Weekends on June 13, 2010. In many ways, these days feel a lot like it did in mid-2010 but there are ...

Alzheimer's disease remains one of the biggest problems of our time. There is no cure for it and all treatment options are supportive. We still can't slow the disease progression effectively. Cortexyme, Inc. (Nasdaq: CRTX ) is a San Francisco-based biotechnology company specializing in a ne...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases, today announced that the International Nonproprietary Naming Committee of t...

The following slide deck was published by Cortexyme, Inc. in conjunction with this Read more ...

-- Presentation to be webcast on Cortexyme’s website Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief exe...

Insider buying decreased significantly last week, with insiders purchasing $107.94 million of stock compared to $305.64 million in the week prior. Selling also decreased, with insiders selling $1.33 billion of stock last week compared to $2.89 billion in the week prior. Most of the management ...

Cortexyme (NASDAQ: CRTX ): Q1 GAAP EPS of -$0.61 misses by $0.17 . More news on: Cortexyme, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

— Interim analysis for the GAIN Trial on track for Q4 2020, with top-line results from study’s final analysis expected in Q4 2021 — Cortexyme shared additional scientific evidence supporting the gingipain hypothesis via multiple presentations and publications ...

-- Presentation to be webcast on Cortexyme’s website Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degene...

  Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s (AD) and other degenerative diseases, today announced the publication ...